Check-vacc - possible complete response case study!, page-31

Thanks @reon1

I missed that. I suspect that you are correct, and I would also suspect that this has the blessing of the professor.

I really likes the recent interview where we were told that going after bile duct cancer is not really about focusing on the market size commercially, but rather to get the therapy approved as quickly as possible. This is because once a therapy is approved it can much more easily be opened up to other indications. While Bile duct cancer revenue will be nothing to be sneezed at, there are far bigger commercial opportunities for cf33 to take on. The real value is the speed in which an fda approval for bile duct cancer may arrive. This in turn will likely improve the overall speed to market/patients for more saturated indications. Chances are, the same strategy applies to chec-vacc. Pause it now, and go hard on it later. Very savvy imo